These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 22798428

  • 1. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.
    Menges CW, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson JR, Testa JR.
    Mol Cancer Res; 2012 Sep; 10(9):1178-88. PubMed ID: 22798428
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Group I Paks as therapeutic targets in NF2-deficient meningioma.
    Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ, Chernoff J.
    Oncotarget; 2015 Feb 10; 6(4):1981-94. PubMed ID: 25596744
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. P21 activated kinase signaling in cancer.
    Rane CK, Minden A.
    Semin Cancer Biol; 2019 Feb 10; 54():40-49. PubMed ID: 29330094
    [Abstract] [Full Text] [Related]

  • 9. Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion.
    Najahi-Missaoui W, Quach ND, Jenkins A, Dabke I, Somanath PR, Cummings BS.
    Pharmacol Res Perspect; 2019 Oct 10; 7(5):e00518. PubMed ID: 31516713
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
    Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR.
    Mol Cell Biol; 2005 Mar 10; 25(6):2384-94. PubMed ID: 15743831
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
    Arias-Romero LE, Villamar-Cruz O, Pacheco A, Kosoff R, Huang M, Muthuswamy SK, Chernoff J.
    Oncogene; 2010 Oct 28; 29(43):5839-49. PubMed ID: 20711231
    [Abstract] [Full Text] [Related]

  • 16. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
    Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M, Fernández-Valle C.
    Oncogene; 2014 Jul 03; 33(27):3571-82. PubMed ID: 23934191
    [Abstract] [Full Text] [Related]

  • 17. p21-activated kinase links Rac/Cdc42 signaling to merlin.
    Xiao GH, Beeser A, Chernoff J, Testa JR.
    J Biol Chem; 2002 Jan 11; 277(2):883-6. PubMed ID: 11719502
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.